CEBP CTRC-AACR San Antonio Breast Cancer Symposium Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wolfe, P.
Right arrow Articles by Thompson, H. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wolfe, P.
Right arrow Articles by Thompson, H. J.
Cancer Epidemiology Biomarkers & Prevention Vol. 13, 976-988, June 2004
© 2004 American Association for Cancer Research

Using Nuclear Morphometry to Discriminate the Tumorigenic Potential of Cells: A Comparison of Statistical Methods

Pamela Wolfe1, James Murphy1, John McGinley2, Zongjian Zhu1, Weiqin Jiang1, E. Brigitte Gottschall2 and Henry J. Thompson1

1 Cancer Prevention Laboratory, Colorado State University, Fort Collins, Colorado and 2 Departments of Biometrics and Occupational Medicine, National Jewish Medical and Research Center, Denver, Colorado

Requests for reprints: Pamela Wolfe, Cancer Prevention Laboratory, Colorado State University, 111 Shepardson Building, 1173 Campus Delivery, Fort Collins, CO 80523. Phone: 303-730-3236; Fax: 970-491-3542. E-mail: wolfe{at}earthlink.net

Despite interest in the use of nuclear morphometry for cancer diagnosis and prognosis as well as to monitor changes in cancer risk, no generally accepted statistical method has emerged for the analysis of these data. To evaluate different statistical approaches, Feulgen-stained nuclei from a human lung epithelial cell line, BEAS-2B, and a human lung adenocarcinoma (non-small cell) cancer cell line, NCI-H522, were subjected to morphometric analysis using a CAS-200 imaging system. The morphometric characteristics of these two cell lines differed significantly. Therefore, we proceeded to address the question of which statistical approach was most effective in classifying individual cells into the cell lines from which they were derived. The statistical techniques evaluated ranged from simple, traditional, parametric approaches to newer machine learning techniques. The multivariate techniques were compared based on a systematic cross-validation approach using 10 fixed partitions of the data to compute the misclassification rate for each method. For comparisons across cell lines at the level of each morphometric feature, we found little to distinguish nonparametric from parametric approaches. Among the linear models applied, logistic regression had the highest percentage of correct classifications; among the nonlinear and nonparametric methods applied, the Classification and Regression Trees model provided the highest percentage of correct classifications. Classification and Regression Trees has appealing characteristics: there are no assumptions about the distribution of the variables to be used, there is no need to specify which interactions to test, and there is no difficulty in handling complex, high-dimensional data sets containing mixed data types.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.